Disease · MONDO_0001660
Comparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 28
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Candesartan vs Placebo: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale | 127 of 951 | 124 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR). | 110 of 951 | 107 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy. | 140 of 951 | 139 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: serious adverse events | 173 of 951 | 161 of 951 | 1,902 | NCT00252720 | Trial comparisons |
| Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 54 for the Study Eye | 108 of 347 | 248 of 341 | 688 | NCT04278417 | Trial comparisons |
| Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 96 for the Study Eye | 126 of 347 | 262 of 341 | 688 | NCT04278417 | Trial comparisons |
| Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 96 for the Study Eye | 188 of 310 | 86 of 303 | 613 | NCT04278417 | Trial comparisons |
| Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 54 for the Study Eye | 187 of 294 | 65 of 290 | 584 | NCT04278417 | Trial comparisons |
| Ranibizumab vs Saline Injection: serious adverse events | 13 of 125 | 23 of 136 | 261 | NCT00996437 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: deaths from any cause | 6 of 100 | 3 of 105 | 205 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: serious adverse events | 44 of 100 | 45 of 105 | 205 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Recurrent Vitreous Hemorrhage | 48 of 97 | 16 of 104 | 201 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 15 of 89 | 2 of 95 | 184 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 25 of 85 | 3 of 92 | 177 | NCT02858076 | Trial comparisons |
| Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Retinal Neovascularization on Clinical Exam | 20 of 88 | 2 of 83 | 171 | NCT02858076 | Trial comparisons |
| Active Laser Photocoagulation and Ranibizumab vs Active Laser Photocoagulation and Sham Injection: serious adverse events | 14 of 85 | 5 of 43 | 128 | NCT01131585 | Trial comparisons |
| Intervention Group vs Control Group: Anatomic Status of the Retina | 0 of 22 | 7 of 18 | 40 | NCT00548197 | Trial comparisons |
| Intervention vs Control: deaths from any cause | 0 of 22 | 0 of 18 | 40 | NCT00548197 | Trial comparisons |
| Intervention vs Control: serious adverse events | 1 of 22 | 1 of 18 | 40 | NCT00548197 | Trial comparisons |
| Q4WKS vs Q12WKS: deaths from any cause | 0 of 20 | 1 of 20 | 40 | NCT02863354 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001660/comparisons